Application of high-throughput, molecular-targeted screening to anticancer drug discovery.
Increasing insight into the genetics and molecular biology of cancer has resulted in the identification of an increasing number of potential molecular targets for anti-cancer drug discovery and development. These targets can be approached through exploitation of emerging structural biology, "rational" drug design, screening of chemical libraries, or a combination of these methods. In this article we discuss the application of high-throughput screening to anti-cancer drug discovery, with special reference to approaches used at the U.S. National Cancer Institute.
Shoemaker
Robert H
RH
Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute-Frederick, Maryland 21702-1201, USA. shoemaker@dtpax2.ncifcrf.gov
Scudiero
Dominic A
DA
Melillo
Giovanni
G
Currens
Michael J
MJ
Monks
Anne P
AP
Rabow
Alfred A
AA
Covell
David G
DG
Sausville
Edward A
EA
D000465:Algorithms; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D020650:Combinatorial Chemistry Techniques / Q000379:methods; D015195:Drug Design; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D006801:Humans
D000970:Antineoplastic Agents